AR064368A1 - COMPOUNDS FOR THE TREATMENT OF SEXUAL DYSFUNCTION SELECTIVE ANTAGONIST OF OPIOID RECEPTORS MU. USE. PHARMACEUTICAL COMPOSITION - Google Patents
COMPOUNDS FOR THE TREATMENT OF SEXUAL DYSFUNCTION SELECTIVE ANTAGONIST OF OPIOID RECEPTORS MU. USE. PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- AR064368A1 AR064368A1 ARP070105640A ARP070105640A AR064368A1 AR 064368 A1 AR064368 A1 AR 064368A1 AR P070105640 A ARP070105640 A AR P070105640A AR P070105640 A ARP070105640 A AR P070105640A AR 064368 A1 AR064368 A1 AR 064368A1
- Authority
- AR
- Argentina
- Prior art keywords
- modulators
- agonists
- selective
- receptor
- piv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Procedimientos de tratamiento de la disfuncion sexual femenina con un antagonista selectivo de los receptores de opioides mu. También se describen tratamientos de combinacion con otras clases de agentes. Reivindicacion 1: Uso de un antagonista selectivo de receptores de opioides mu caracterizado porque es en la preparacion de un medicamento para el tratamiento y/o la prevencion de la disfuncion sexual femenina (DSF). Reivindicacion 18: Uso de acuerdo con la reivindicacion 17, caracterizado porque el compuesto es mesilato de Exo-N-{3-[6-etil-3-(2-hidroxi-indan-2-ilmetil)-3-aza-biciclo[3.1.0]hex-6-il]-fenil}-metanosulfonamida. Reivindicacion 19: Uso de un antagonista selectivo de los receptores de opioides mu junto con un agente auxiliar caracterizado porque se selecciona de uno o más de: i) compuestos que modulan la accion de factores natriuréticos, en particular del factor natriurético atrial; ii) compuestos que inhiben la enzima convertidora de angiotensina; iii) sustratos de la NO sintasa; iv) agentes reductores del colesterol; v) moduladores de los receptores de estrogeno y/o agonistas de estrogenos y/o antagonistas de estrogenos; vi) inhibidores de la fosfodiesterasa (PDE); vii) proteína intestinal vasoactiva (PIV), mimético de la PIV, análogo de la PIV, un agonista del receptor de la PIV o un fragmento de la PIV o una combinacion de un antagonista de los adrenoceptores con PIV; viii) agonistas, antagonista o moduladores de los receptores de serotonina; ix) agentes sustitutorios de la testosterona o implantes de testosterona; x) moduladores selectivo de receptor de androgenos; xi) estrogeno, estrogeno y medroxiprogesterona o acetato de medroxiprogesterona (MPA) (es decir, en forma de combinacion) o estrogeno y agente de tratamiento sustitutorio hormonal de metiltestosterona; xii) progesterona, agonistas o moduladores de la progesterona tales como Gestodine, etinilestradiol, etinodiol, implante de etonogesterol, dihidrogesterona, progestogeno, totelle sekvens, noretinodrel o cremas o geles de progesterona tales como MuProgest, Natragest y Fem-Gest; xiii) moduladores de transportadores para noradrenalina, dopamina y/o serotonina; y xiv) agonistas o moduladores de los receptores de oxitocina/vasopresina; xv) agonistas o moduladores del receptor de melanocortina; xvi) inhibidores del transporte de monoamina; xvii) agonistas de dopamina (en particular agentes selectivos de D2, selectivos de D3, selectivos de D4 y selectivos de tipo D2); xviii) antagonistas de los receptores alfa-adrenérgicos (también conocidos como bloqueantes de alfa-adrenoceptores, bloqueantes de alfa-receptores o bloqueantes), xix) agentes anti-diabéticos; y xx) moduladores del receptor NPY (agonistas y/o antagonistas) en la preparacion de un medicamento para el tratamiento y/o prevencion de la disfuncion sexual femenina. Reivindicacion 20: Una composicion farmacéutica caracterizada porque comprende un antagonista selectivo de receptores de opioides mu y uno o más agentes auxiliares seleccionados de: i) compuestos que modulan la accion de factores natriuréticos, en particular del factor natriurético atrial; ii) compuestos que inhiben la enzima convertidora de angiotensina; iii) sustratos de la NO sintasa; iv) agentes reductores del colesterol; v) moduladores de los receptores de estrogeno y/o agonistas de estrogenos y/o antagonistas de estrogenos; vi) inhibidores de la fosfodiesterasa (PDE); vii proteína intestinal vasoactiva (PIV), mimético de la PIV, análogo de la PIV, un agonista del receptor de la PIV o un fragmento de la PIV o una combinacion de un antagonista de los adrenoceptores con PIV; viii) agonistas, antagonistas o moduladores de los receptores de serotonina; ix) agentes sustitutorios de la testosterona o implantes de testosterona; x) moduladores selectivos de receptor de androgenos; xi) estrogeno, estrogeno y medroxiprogesterona o acetato de medroxiprogesterona (MPA) (es decir, en forma de combinacion) o estrogeno y agentes de tratamiento sustitutorio hormonal de metiltestosterona; xii) progesterona, agonistas o moduladores de la progesterona tales como Gestodine, etinilestradiol, etinodiol, implante de etonogesterol, dihidrogesterona, progestogeno, totelle sekvens, noretinodrel o cremas o geles de progesterona tales como MuProgest, Natragest y Fem-Gest; xiii) moduladores de transportadores para noradrenalina, dopamina y/o serotonina; y xiv) agonistas o moduladores de los receptores de oxitocina/vasopresina; xv) agonistas o moduladores del receptor de melanocortina; xvi) inhibidores del transporte de monoamina; xvii) agonistas de dopamina (en particular agentes selectivos de D2, selectivos de D3, selectivos de D4 y selectivos de tipo D2); xviii) antagonistas de los receptores alfa-adrenérgicos (también conocidos como bloqueantes de alfa-adrenoceptores, bloqueantes de alfa-receptores o bloqueantes), xix) agentes anti-diabéticos; y xx) moduladores del receptor NPY (agonistas y/o antagonistas). Reivindicacion 21: Un antagonista selectivo de receptores de opioides mu caracterizado porque es para usar en el tratamiento y/o prevencion de la disfuncion sexual femenina (DSF).Procedures for treating female sexual dysfunction with a selective opioid receptor antagonist mu. Combination treatments with other classes of agents are also described. Claim 1: Use of a selective opioid receptor antagonist characterized in that it is in the preparation of a medicament for the treatment and / or prevention of female sexual dysfunction (DSF). Claim 18: Use according to claim 17, characterized in that the compound is Exo-N- {3- [6-ethyl-3- (2-hydroxy-indan-2-ylmethyl) -3-aza-bicyclo [ 3.1.0] hex-6-yl] -phenyl} -methanesulfonamide. Claim 19: Use of a selective opioid receptor antagonist together with an auxiliary agent characterized in that it is selected from one or more of: i) compounds that modulate the action of natriuretic factors, in particular atrial natriuretic factor; ii) compounds that inhibit the angiotensin converting enzyme; iii) NO synthase substrates; iv) cholesterol lowering agents; v) estrogen receptor modulators and / or estrogen agonists and / or estrogen antagonists; vi) phosphodiesterase (PDE) inhibitors; vii) vasoactive intestinal protein (PIV), PIV mimetic, PIV analogue, a PIV receptor agonist or a PIV fragment or a combination of an adrenoceptor antagonist with PIV; viii) agonists, antagonists or modulators of serotonin receptors; ix) testosterone replacement agents or testosterone implants; x) selective androgen receptor modulators; xi) estrogen, estrogen and medroxyprogesterone or medroxyprogesterone acetate (MPA) (i.e., in combination) or estrogen and methyltestosterone hormone replacement therapy agent; xii) progesterone, agonists or modulators of progesterone such as Gestodine, ethinyl estradiol, ethinodiol, implant of etonogesterol, dihydrogesterone, progestogen, totelle sekvens, noretinodrel or creams or gels of progesterone such as MuProgest, Natragest and Fem; xiii) transporter modulators for norepinephrine, dopamine and / or serotonin; and xiv) oxytocin / vasopressin receptor agonists or modulators; xv) melanocortin receptor agonists or modulators; xvi) monoamine transport inhibitors; xvii) dopamine agonists (in particular selective agents of D2, selective of D3, selective of D4 and selective of type D2); xviii) alpha-adrenergic receptor antagonists (also known as alpha-adrenoceptor blockers, alpha-receptor blockers or blockers), xix) anti-diabetic agents; and xx) NPY receptor modulators (agonists and / or antagonists) in the preparation of a medicament for the treatment and / or prevention of female sexual dysfunction. Claim 20: A pharmaceutical composition characterized in that it comprises a selective opioid receptor antagonist mu and one or more auxiliary agents selected from: i) compounds that modulate the action of natriuretic factors, in particular atrial natriuretic factor; ii) compounds that inhibit the angiotensin converting enzyme; iii) NO synthase substrates; iv) cholesterol lowering agents; v) estrogen receptor modulators and / or estrogen agonists and / or estrogen antagonists; vi) phosphodiesterase (PDE) inhibitors; vii vasoactive intestinal protein (PIV), PIV mimetic, PIV analogue, a PIV receptor agonist or a PIV fragment or a combination of an adrenoceptor antagonist with PIV; viii) agonists, antagonists or modulators of serotonin receptors; ix) testosterone replacement agents or testosterone implants; x) selective androgen receptor modulators; xi) estrogen, estrogen and medroxyprogesterone or medroxyprogesterone acetate (MPA) (i.e., in combination form) or estrogen and methyltestosterone hormone replacement therapy agents; xii) progesterone, agonists or modulators of progesterone such as Gestodine, ethinyl estradiol, ethinodiol, implant of etonogesterol, dihydrogesterone, progestogen, totelle sekvens, noretinodrel or creams or gels of progesterone such as MuProgest, Natragest and Fem; xiii) transporter modulators for norepinephrine, dopamine and / or serotonin; and xiv) oxytocin / vasopressin receptor agonists or modulators; xv) melanocortin receptor agonists or modulators; xvi) monoamine transport inhibitors; xvii) dopamine agonists (in particular selective agents of D2, selective of D3, selective of D4 and selective of type D2); xviii) alpha-adrenergic receptor antagonists (also known as alpha-adrenoceptor blockers, alpha-receptor blockers or blockers), xix) anti-diabetic agents; and xx) NPY receptor modulators (agonists and / or antagonists). Claim 21: A selective opioid receptor antagonist mu characterized in that it is for use in the treatment and / or prevention of female sexual dysfunction (DSF).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87019306P | 2006-12-15 | 2006-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064368A1 true AR064368A1 (en) | 2009-04-01 |
Family
ID=39387090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105640A AR064368A1 (en) | 2006-12-15 | 2007-12-14 | COMPOUNDS FOR THE TREATMENT OF SEXUAL DYSFUNCTION SELECTIVE ANTAGONIST OF OPIOID RECEPTORS MU. USE. PHARMACEUTICAL COMPOSITION |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2008150371A (en) |
AR (1) | AR064368A1 (en) |
TW (1) | TW200833338A (en) |
WO (1) | WO2008075162A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013007566A2 (en) | 2010-09-28 | 2016-08-02 | Panacea Biotec Ltd | new bicyclic compounds |
PL2694065T3 (en) * | 2011-04-04 | 2018-06-29 | S1 Biopharma, Inc. | Composition for treating hypoactive sexual desire disorder |
WO2014025814A1 (en) | 2012-08-06 | 2014-02-13 | S1 Pharmaceuticals, Inc. | Treatment regimens |
EP3072884B1 (en) | 2013-11-20 | 2020-01-01 | Sanwa Kagaku Kenkyusho Co., Ltd. | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes |
AU2016265801B2 (en) | 2015-05-20 | 2020-10-08 | Ube Corporation | Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0213464A (en) * | 2001-10-22 | 2004-11-09 | Pfizer Prod Inc | 3-Azabicyclo [3.1.0] hexane derivatives as opioid receptor antagonists |
SI2316456T1 (en) * | 2003-04-29 | 2017-10-30 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
JP2007508367A (en) * | 2003-10-16 | 2007-04-05 | ファイザー・プロダクツ・インク | Method for producing 3-azabicyclo [3.1.0] hexane derivative |
US7087749B2 (en) * | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
-
2007
- 2007-12-03 WO PCT/IB2007/003884 patent/WO2008075162A2/en active Application Filing
- 2007-12-11 JP JP2007319381A patent/JP2008150371A/en active Pending
- 2007-12-14 TW TW096147979A patent/TW200833338A/en unknown
- 2007-12-14 AR ARP070105640A patent/AR064368A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008075162A3 (en) | 2008-10-23 |
TW200833338A (en) | 2008-08-16 |
JP2008150371A (en) | 2008-07-03 |
WO2008075162A2 (en) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064368A1 (en) | COMPOUNDS FOR THE TREATMENT OF SEXUAL DYSFUNCTION SELECTIVE ANTAGONIST OF OPIOID RECEPTORS MU. USE. PHARMACEUTICAL COMPOSITION | |
Hofbauer et al. | Androgen effects on bone metabolism: recent progress and controversies | |
Perlmutter et al. | Androgen deprivation therapy in the treatment of advanced prostate cancer | |
US7186838B2 (en) | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | |
PE20070329A1 (en) | COMPOSITIONS WITH ESTROGENS AND THERAPEUTIC METHODS FOR THEIR USE | |
CL2011003172A1 (en) | Pharmaceutical composition comprising a) an exception, b) at least one sex steroid precursor, c) at least one selective estrogen receptor modulator or an antiestrogen and does not contain a progestin and / or an estrogen; pharmaceutical kit; and use to reduce or eliminate hot flashes, vasomotor symptoms, and night sweats. | |
PE20020082A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1) | |
CO5150222A1 (en) | METHOD AND COMBINATION USING (-) NORCISAPRIDA IN COMBINATION WITH PROTON PUMP INHIBITORS OR RECEIVER ANTAGONISTS H [sub 2] | |
EP1778242A4 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
AU2002330031B2 (en) | Androstanes as androgen receptor modulators | |
SG155258A1 (en) | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausa | |
UY30109A1 (en) | PHARMACOLOGICAL FORMS IN THE FORM OF A FILM FOR USE IN THE ORAL CAVITY (OBLEAS) | |
NI201000183A (en) | ANTIPROGESTIN DOSAGE REGIMES. | |
MX2012014579A (en) | Methods of treating or preventing estrogen-related diseases. | |
HN2008000621A (en) | METHOD FOR PREVENTIVE HORMONAL ANTICOPCEPTION UNDER DEMAND | |
CO5150232A1 (en) | METHOD AND COMBINATION USING (+) NORCISAPRIDA IN COMBINATION WITH PROTON PUMP INHIBITORS OR RECEIVER ANTAGONISTS H [sub 2] | |
TW200619202A (en) | Indazoles, benzisoxazoles and benzisothiazoles, process for preparing them, pharmaceutical compositions and use as estrogenic agents | |
TW200738269A (en) | Oral delivery of therapeutic agents using tight junction agonists | |
JP2008504263A (en) | Estrogen receptor modulator | |
JP2006528686A (en) | Androgen receptor modulators and their use | |
US7402577B2 (en) | Androstane 17-beta-carboxamides as androgen receptor modulators | |
MXPA05010871A (en) | Methods of administering estrogens and progestins. | |
AU2002331916A1 (en) | Androstane 17-beta-carboxamides as androgen receptor modulators | |
JP4563032B2 (en) | 17-Hydroxy-4-aza-androstan-3-one as an androgen receptor modulator | |
WO2003002058A2 (en) | Bone anabolic compounds and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |